Curated dataset · n=61 verified deals · Not live market data · Scores are descriptive, not forecasts.
You are here

Deals — Network graph, deal flow, valuation matrix, and acquirer landscape.

IVI-RMA Global
→
KKR

Acquisition · Cash (leveraged buyout) · announced Mar 1, 2022

View in network
  1. Announced

    Mar 1, 2022

  2. Closed

    Jan 18, 2023

Economics

Cash (leveraged buyout)()

Pre-deal · pre-deal mark: 2022, year precision · rounding grid ±$100M · KKR press release — IVI-RMA Global acquisition, 2023

~€3B ($3.25B) for 80% stake; world's largest fertility clinic acquisition; founders retained 20%

Target

IVI-RMA Global

Fertility · Fertility science

HQ Valencia, Spain · Founded 1990

World's largest fertility clinic network; 75+ clinics and 28 labs in 9 countries; formed from 2017 merger of Spain's IVI and US-based RMANJ

  • Axios Pro (April 13, 2022) - deal announcement
  • Fertility Bridge (January 26, 2023) - deal close confirmation
  • Spanish CNMC regulatory approval (December 21, 2022)

Acquirer

KKR

Healthcare

HQ New York, NY

Global investment firm; major investor in fertility clinic consolidation

Why this buyer

Curated copy from the verified dataset — not an 8-K LLM summary

Created world's largest fertility services group by combining IVI-RMA with KKR's prior GeneraLife acquisition; 75+ clinics in 9 countries

Evidence ladder

Press only — no primary filingValue disclosed
  1. Tertiary (trade / analyst)

    Axios Pro (April 13, 2022)

  2. Tertiary (trade / analyst)

    Fertility Bridge (January 26, 2023)

  3. Tertiary (trade / analyst)

    CNMC approval (December 21, 2022)

Limitations

  • Citations are press/IR only — two wires of the same announcement are not dual-source. Add a primary filing.
  • ~€3B ($3.25B) for 80% stake; world's largest fertility clinic acquisition; founders retained 20%
  • Pre-deal valuation sourced from: KKR press release — IVI-RMA Global acquisition, 2023. Pre-deal market-cap and funding citations do not corroborate the acquisition.

Valuation peers · Fertility

Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.

Insufficient disclosed data

No verified Fertility deals meet the peer rule: same deal type, announced within ±3 years, and a disclosed value inside 0.25×–4× of this transaction.

Same-sector adjacency — not valuation peers

These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.

Vs this deal
Indira IVFBPEA EQTJul 28, 2023
Eugin Group (North American operations)KKR (via IVI-RMA)Nov 1, 2023
Hamilton ThorneAstorgJul 22, 2024
Modern FertilityRoMay 19, 2021

Other verified deals by KKR

Acquirer program history not already listed as a valuation peer or adjacency row.

No further verified deals

Other verified transactions by KKR are already listed above, or none are in the dataset.

Patient empowerment context

Patient empowerment baseline (HLTH 2022)

No curated mapping — IVI-RMA Global (Fertility). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.

Research workspace (includes heuristic crosswalk) →

Related verified workspaces

Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.

Curated verified dataset v11 · updated 2026-10-19 · 3 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.